Literature DB >> 7685795

Studies on antigen binding by intact and hinge-deleted chimeric antibodies.

C Horgan1, K Brown, S H Pincus.   

Abstract

A matched set of chimeric IgG1 and IgG4 antibodies were used to investigate the role of the IgG hinge in binding to Ag with differing space between the epitopes. Antibodies bearing identical V regions and either IgG1 or IgG4 C regions were engineered with and without hinges. We measured the binding of these antibodies to the peptide CYYYEEEEY and to CYYYEEEEY-BSA conjugates with decreasing numbers of peptides per BSA molecule. We earlier showed that V region differences in antibodies could affect Ag binding patterns in solid-phase but not solution-phase assays; however, both types of assay yielded similar results for the hinge-deleted antibodies. Binding of CYYYEEEEY-BSA by hinge-deleted and intact IgG1 was similar, but intact IgG1 bound free peptide better than did hinge-deleted IgG1. Intact IgG4 antibody bound less well to CYYYEEEEY and CYYYEEEEY-BSA than did IgG1 but, surprisingly, hinge-deleted IgG4 showed better binding than did intact IgG4 and was more like the IgG1 antibodies in binding affinity. Thus, the IgG4 hinge may impart a structural constraint that prevents high affinity binding to Ag. The hinge-deleted IgG4 antibody did not activate C, although it bound Ag similarly to IgG1. This study is the first to address the effect of the IgG hinge on Ag binding by using well defined Ag with different epitope densities. Our results may provide an explanation for the apparent low affinity of IgG4 antibodies.

Mesh:

Substances:

Year:  1993        PMID: 7685795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies?

Authors:  O Pritsch; G Hudry-Clergeon; M Buckle; Y Petillot; J P Bouvet; J Gagnon; G Dighiero
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

Review 2.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

3.  Reorienting the Fab domains of trastuzumab results in potent HER2 activators.

Authors:  Justin M Scheer; Wendy Sandoval; J Michael Elliott; Lily Shao; Elizabeth Luis; Sock-Cheng Lewin-Koh; Gabriele Schaefer; Richard Vandlen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

4.  Nanopore-based kinetics analysis of individual antibody-channel and antibody-antigen interactions.

Authors:  Stephen Winters-Hilt; Eric Morales; Iftekhar Amin; Alexander Stoyanov
Journal:  BMC Bioinformatics       Date:  2007-11-01       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.